SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-053503
Filing Date
2020-04-29
Accepted
2020-04-29 17:00:02
Documents
5
Period of Report
2020-04-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2015182-2_8k.htm 8-K 23424
2 EXHIBIT 1.1 tm2015182d2_ex1-1.htm EX-1.1 204324
3 EXHIBIT 5.1 tm2015182d2_ex5-1.htm EX-5.1 13361
4 GRAPHIC tm2015182d2_ex5-1img001.jpg GRAPHIC 32939
5 GRAPHIC tm2015182d2_ex5-1img002.jpg GRAPHIC 17287
  Complete submission text file 0001104659-20-053503.txt   312043
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 20831300
SIC: 2834 Pharmaceutical Preparations